Trial Profile
An Open-Label Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Subjects With Hepatocellular Carcinoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 Dec 2023
Price :
$35
*
At a glance
- Drugs Lenvatinib (Primary) ; Pembrolizumab (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms KEYNOTE-524
- Sponsors Eisai Co Ltd
- 13 Jan 2023 Status changed from active, no longer recruiting to completed.
- 07 Mar 2022 Planned End Date changed from 30 Sep 2022 to 30 Nov 2022.
- 15 Dec 2021 This trial has been completed in Japan, according to Japan Pharmaceutical Information Center - Clinical Trials Information record.